glp 1 drugs india GLP-1 Patents Are Fading - Can Lead the Generics Market? India's GLP-1 market enters slower
Description
Glucagon secretion decreases
)
Cost is a significant issue, one physician said
What raises concerns are some of the recent reports of serious ADRs associated with GLP-1RAs: (i) Pfizers disclosure of elevated aminotransferases in users of lotiglipron (a novel oral GLP-1RA) is indicative of hepatocellular injury [11]
Some of them are working additional jobs or delaying retirement so they can continue to pay for it. Both Lilly and Novo have already cut prices on their drugs
Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, et al
)
Retrieved from Wilding, J
